MeSH tree: N06.850.520.830.998
Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic ...
Sep 12, 2026
0
10
The phase 3 TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared ...
Sep 12, 2026
0
6
Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated small cell lung ...
Sep 12, 2026
0
27
Mayo Clinic researchers have found that artificial intelligence (AI)-enabled spatial analysis can identify patterns in routine pathology slides that may help clinicians identify which patients with pancreatic cancer are at ...
Sep 11, 2026
0
5
Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors responded to neoadjuvant immunochemotherapy (ICT) and who underwent less extensive surgery had high disease-free survival and organ ...
Sep 10, 2026
0
11
Results of the NRG Oncology NRG-GU005 clinical study comparing stereotactic body radiation therapy (SBRT) with moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) for patients with localized intermediate-risk ...
Aug 25, 2026
0
9
The cost-effectiveness of the immunotherapy drug pembrolizumab for patients with locally advanced head and neck squamous cell carcinoma may depend on biomarker results, according to a new study.
Aug 10, 2026
0
6
Community gathering places, where residents lead group activities, have been promoted across Japan as part of long-term care prevention efforts to extend healthy life expectancy. These often involve exercise and social interaction ...
Jul 31, 2026
0
6
Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab ...
Jul 30, 2026
0
9
An international team of researchers led by the Barcelona Institute for Global Health (ISGlobal) and the University of Bonn—with participation from the Barça Innovation Hub (BIHUB), FC Barcelona's medical department and the ...
Jul 28, 2026
0
8
